See the DrugPatentWatch profile for ruxolitinib

Based on the information available, the excipients in Apotex's SR Ruxolitinib formulation are hypromellose, polyethylene glycol, talc, and titanium dioxide.

Excipients are inactive substances that serve as vehicles or mediums for a drug. They may be used to provide bulk, improve the drug's stability or appearance, or aid in the manufacturing process.

In the case of Apotex's SR (sustained release) Ruxolitinib formulation, the following excipients are used:

1. Hypromellose: This is a cellulose derivative that is often used as a binder or film former in pharmaceutical tablets. It can help to improve the drug's stability and control the release of the active ingredient.

2. Polyethylene glycol: This is a polymer that is often used as a binder or solvent in pharmaceutical tablets. It can help to improve the drug's stability and aid in the manufacturing process.

3. Talc: This is a mineral that is often used as a filler or lubricant in pharmaceutical tablets. It can help to improve the drug's flow properties and prevent the tablets from sticking together.

4. Titanium dioxide: This is a mineral that is often used as a colorant or opacifying agent in pharmaceutical tablets. It can help to improve the drug's appearance and make it easier to swallow.

It's important to note that the exact composition of a drug formulation can vary depending on the manufacturer and the specific formulation. For more information on the excipients in Apotex's SR Ruxolitinib formulation, you may wish to consult the drug's prescribing information or contact the manufacturer directly.

Sources:

1. DrugPatentWatch.com. (n.d.). Ruxolitinib. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>.
2. U.S. Food and Drug Administration. (2015). JAKAVI (ruxolitinib) tablets for oral use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203087s000lbl.pdf>.
3. Apotex Corp. (2018). RUXOLITINIB TABLETS, FOR ORAL USE. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208032s000lbl.pdf>.